Collegium Pharmaceutical (NASDAQ:COLL) has been given a $33.00 price target by investment analysts at Needham & Company LLC in a report issued on Friday, TipRanks reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 187.46% from the company’s previous close.
Several other equities research analysts have also issued reports on the stock. BidaskClub upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $24.00 price target (down from $35.00) on shares of Collegium Pharmaceutical in a research note on Thursday, August 8th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 8th. ValuEngine upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, William Blair reiterated a “buy” rating on shares of Collegium Pharmaceutical in a research note on Tuesday, September 17th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $24.33.
COLL traded up $0.03 during trading on Friday, hitting $11.48. The company had a trading volume of 298,776 shares, compared to its average volume of 358,696. The company has a market capitalization of $384.25 million, a PE ratio of -9.65 and a beta of 0.52. Collegium Pharmaceutical has a one year low of $10.01 and a one year high of $19.83. The firm’s 50-day moving average price is $11.48 and its 200 day moving average price is $12.85. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 0.23.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The firm had revenue of $75.04 million for the quarter, compared to analyst estimates of $75.77 million. During the same period in the previous year, the business earned ($0.40) EPS. The company’s revenue was up 2.7% compared to the same quarter last year. Sell-side analysts forecast that Collegium Pharmaceutical will post -0.36 earnings per share for the current year.
In other news, Director David Hirsch sold 22,106 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $11.65, for a total transaction of $257,534.90. Following the transaction, the director now directly owns 64,223 shares in the company, valued at approximately $748,197.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 2,857 shares of the business’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $12.31, for a total transaction of $35,169.67. Following the transaction, the executive vice president now owns 40,596 shares in the company, valued at $499,736.76. The disclosure for this sale can be found here. Insiders sold a total of 49,963 shares of company stock worth $574,205 over the last quarter. Company insiders own 8.08% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. First Quadrant L P CA increased its stake in shares of Collegium Pharmaceutical by 87.2% during the 2nd quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 2,089 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Collegium Pharmaceutical by 67,855.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock worth $93,000 after purchasing an additional 6,107 shares during the last quarter. Paradigm Capital Management Inc. NY acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth about $131,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth about $137,000. Finally, Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth about $196,000. Institutional investors own 92.08% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Featured Story: What are the benefits of momentum investing?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.